Regulus Therapeutics Inc. financial data

Symbol
RGLS on Nasdaq
Industry
Pharmaceutical Preparations
Location
4224 Campus Point Court, Suite 210, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.51K % +266%
Debt-to-equity 7.38 % -79.3%
Return On Equity -50.3 % +54%
Return On Assets -46.8 % +41.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66.2M shares +1.19%
Common Stock, Shares, Outstanding 65.5M shares +224%
Entity Public Float 115M USD +319%
Common Stock, Value, Issued 66K USD +230%
Weighted Average Number of Shares Outstanding, Basic 56.3M shares +197%
Weighted Average Number of Shares Outstanding, Diluted 56.3M shares +197%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 35.4M USD +67.2%
General and Administrative Expense 14.7M USD +47.4%
Operating Income (Loss) -50M USD -60.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -46.4M USD -54.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -46.4M USD -54.3%
Earnings Per Share, Basic -0.82 USD/shares +48.1%
Earnings Per Share, Diluted -0.82 USD/shares +48.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 38.5M USD +62.1%
Cash, Cash Equivalents, and Short-term Investments 75.8M USD +218%
Other Assets, Current 1.09M USD -11.5%
Assets, Current 82.3M USD +192%
Property, Plant and Equipment, Net 937K USD -11.7%
Operating Lease, Right-of-Use Asset 874K USD -40.8%
Intangible Assets, Net (Excluding Goodwill) 25K USD -24.2%
Other Assets, Noncurrent 21K USD
Assets 84.2M USD +174%
Accounts Payable, Current 947K USD +364%
Employee-related Liabilities, Current 3.89M USD +30.6%
Accrued Liabilities, Current 746K USD +7.96%
Liabilities, Current 7.5M USD -11.9%
Operating Lease, Liability, Noncurrent 274K USD -74%
Liabilities 7.77M USD -18.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 50K USD
Retained Earnings (Accumulated Deficit) -560M USD -9.03%
Stockholders' Equity Attributable to Parent 76.4M USD +261%
Liabilities and Equity 84.2M USD +174%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.74M USD -7.74%
Net Cash Provided by (Used in) Financing Activities 93.1M USD
Net Cash Provided by (Used in) Investing Activities -78.5M USD -624%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 65.5M shares +224%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 5.82M USD -4.29%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 38.6M USD +61.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 45K USD -69.6%
Deferred Tax Assets, Valuation Allowance 153M USD +9.28%
Deferred Tax Assets, Gross 154M USD +9.2%
Operating Lease, Liability 1.06M USD -40.3%
Payments to Acquire Property, Plant, and Equipment 229K USD +22800%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -46.3M USD -54.2%
Lessee, Operating Lease, Liability, to be Paid 1.1M USD -42.1%
Property, Plant and Equipment, Gross 5.52M USD +4.03%
Operating Lease, Liability, Current 781K USD +9.54%
Lessee, Operating Lease, Liability, to be Paid, Year Two 277K USD -66.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 824K USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 46K USD -65.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 95.9M USD +3.54%
Unrecognized Tax Benefits 7.04M USD +12.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Depreciation, Depletion and Amortization 81K USD +68.8%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 7.74M USD +176%
Interest Expense 500K USD -30.4%